AbbVie is borrowing heavily to buy a company that sells nothing

A biopharmaceutical company that already carries one of the largest debt loads in healthcare has announced the acquisition of another company that sells no approved drugs, and expects to fund the deal with debt. The acquisition target still has to clear Phase 3 trials and regulatory review. The whole transaction is designed to be accretive to adjusted diluted EPS beginning in 2032.

That is a very expensive, very long-dated venture capital check, dressed up as a senior bond offering and a strategic acquisition.

The target is Apogee Therapeutics. AbbVie announced the deal on June 22, offering $135.11 per share in cash for a total equity value of approximately $10.9 billion. Apogee's lead asset, zumilokibart, is a half-life-extended antibody targeting IL-13 - a late-stage molecule with positive Phase 2 data in atopic dermatitis and potential for monthly or quarterly dosing. It also has a combination pipeline aimed at asthma. Both are interesting bets. Both are unproven products. And both are now going to sit on AbbVie's balance sheet, behind AbbVie's credit, funded by AbbVie's new borrowing.

What I can confirm from SEC filings is that AbbVie was already in the market earlier this year, pricing an $8 billion aggregate principal amount of unsecured senior notes in March with maturities running from 2028 through 2066. Whether the debt is raised through a single issuance or layered across facilities, the structural point is the same: AbbVie is pulling cash out of the bond market to buy clinical-stage assets that won't generate revenue for years.

Here is what is odd about the numbers. AbbVie's own public guidance says the Apogee acquisition will become accretive to adjusted diluted EPS beginning in 2032. That is six years away. The new senior notes carry interest obligations that start immediately. In the first quarter of 2026 alone, AbbVie's net interest expense was $645 million. Funding the Apogee acquisition with debt will increase that number, starting now, while the revenue it's supposed to fund won't appear until the 2030s.

That gap - interest costs today, product revenue much later - is the fundamental shape of the trade. It's not unusual for big pharma to take on debt for M&A. But the maturity mismatch here is conspicuous. You can think of it as the bond market being asked to underwrite a clinical-stage pipeline, with the bondholders absorbing the interest drag while the equity holders wait to see if the science works.

AbbVie is not a normal borrower, which is why the bond market is willing to lend. When it spun off from Abbott Laboratories in 2013, it inherited roughly $40 billion in debt as part of the separation consideration. Since then, it has been paying that down while using its strong cash flows from Humira and, more recently, Skyrizi and Rinvoq, to fund a series of acquisitions.

The cash flows are the plumbing that makes this work. Skyrizi brought in Global Skyrizi net revenues were $5.505 billion in the second quarter alone. Rinvoq added another $2.5 billion. Immunology revenue as a whole was $8.8 billion for the quarter, up 15 percent. Worldwide net revenues hit $17 billion, with a first-quarter adjusted operating margin of 40.8 percent. The bond market is not lending to a speculative company. It's lending to a machine that generates enormous, unusually sticky cash flows from chronic-disease therapeutics.

The credit story is therefore not whether AbbVie can service the interest. It's whether AbbVie's management is making a capital allocation call that equity holders should support.

AbbVie's official framing is standard for a deal of this shape. Chairman and CEO Robert Michael called it a move that "strengthens our ability to deliver innovative medicines to patients, bolsters our immunology leadership and creates significant shareholder value." The company also stated it expects to maintain its A2/A- credit rating and target 2x net leverage within two to three years of close.

That credit target is the interesting contractual detail. A 2x net debt-to-EBITDA ratio is, in pharma-acquisition world, a promise of discipline. It means AbbVie isn't intending to keep stacking debt indefinitely. But it also means the clock is ticking on bringing the leverage back down. The new notes will push the ratio higher before Apogee can generate any offsetting EBITDA. The two-to-three-year window to get back to 2x assumes the broader business continues generating cash at current levels, with no other major spending alongside.

There's another angle worth sitting with. AbbVie's Enterprise Value is $521,905 Mil. The stock trades at roughly 26 times EV-to-free-cash-flow - already a premium valuation for a company navigating the Humira sunset. The new debt service is an increment on top of that existing premium. Based on the March offering structure, the notes across various maturities carry coupons in the 3.8 percent to 5.7 percent range. AbbVie is using debt at roughly that band to buy pipeline assets whose returns depend on regulatory approvals, commercial execution, and pricing in categories that may or may not support the implied valuation.

If zumilokibart becomes a $2 billion-plus drug in atopic dermatitis, the math works out. If it underperforms, the interest expense is still real and the leverage ratio is still higher. The bondholders get their coupon regardless.

This is not a new structure. Big pharmaceutical companies have long used their credit ratings and predictable cash flows to finance bolt-on acquisitions. The pattern - borrow against today's blockbusters to buy tomorrow's pipeline - runs through most of the sector's M&A history. The difference here is the gap. Six years to accretion is a long time to ask bondholders to carry interest costs for a product that still has to reach patients.

The Apogee deal is not obviously a bad bet. Atopic dermatitis is a large, underserved market. An IL-13 antibody with quarterly dosing would be commercially attractive. AbbVie has the sales infrastructure to scale it. The $10.9 billion price is not absurd for what Apogee offers.

But the financing tells you what AbbVie is actually betting on. The bet is not just on Apogee's science. The bet is on AbbVie's own cash flow durability over the next six years, its ability to maintain its credit profile while leverage temporarily rises, and its willingness to carry the interest drag until the pipeline matures.

The machine works because AbbVie's current drugs are still printing cash. It remains fragile if those cash flows soften faster than the new assets come online. The interesting number isn't the amount borrowed. It's the six-year gap between the borrowing and the payoff - and the fact that the people who will pay the interest aren't the same people who have to wait for the upside.